Profile data is unavailable for this security.
About the company
Moderna, Inc. is engaged in transformative medicines based on messenger ribonucleic acid (mRNA). It has created a platform to improve the underlying pharmaceutical properties of our mRNA medicines. Its platform consists of three areas: mRNA technologies, delivery technologies, and manufacturing processes. It is pursuing mRNA science to minimize the undesirable activation of the immune system by mRNA and to maximize the potency of mRNA once in the target cells. It has advanced in parallel a diverse development pipeline of 21 programs, of which 10 have entered clinical studies and another three have open INDs. Its therapeutics and vaccine development programs span infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases. It has created six modalities prophylactic vaccines, cancer vaccines, intratumoral immmuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics and systemic intracellular therapeutics.
- Revenue in USD (TTM)105.84m
- Net income in USD-487.25m
- Incorporated2016
- Employees830.00
- LocationModerna Inc200 Technology SqCambridge 02139-3578United StatesUSA
- Phone+1 (617) 714-6500
- Fax+1 (617) 583-1998
- Websitehttps://www.modernatx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Catalent Inc | 2.87bn | 109.80m | 14.29bn | 12.30k | 118.20 | 6.22 | 40.62 | 4.98 | 0.7428 | 0.7428 | 19.29 | 18.04 | 0.4964 | 6.82 | 4.36 | 233,528.50 | 2.38 | 3.69 | 2.72 | 4.22 | 31.51 | 31.81 | 4.79 | 6.47 | 1.55 | 2.05 | 0.5337 | 0.00 | 2.22 | 6.62 | 8.87 | 48.70 | 12.25 | -- |
| Horizon Therapeutics PLC | 1.52bn | 517.40m | 15.15bn | 1.23k | 29.29 | 6.06 | 19.53 | 9.98 | 2.45 | 2.45 | 7.65 | 11.83 | 0.3681 | 6.72 | 3.23 | 1,264,749.00 | 12.55 | -0.3444 | 15.62 | -0.4104 | 73.39 | 64.95 | 34.09 | -1.19 | 1.45 | 2.42 | 0.3326 | -- | 7.66 | 34.35 | 856.24 | -- | 38.53 | -- |
| Cardinal Health Inc | 153.59bn | -4.16bn | 15.71bn | 49.50k | -- | 13.06 | -- | 0.1023 | -14.04 | -14.04 | 519.75 | 4.12 | 3.75 | 11.53 | 18.18 | 3,102,748.00 | -10.14 | 2.60 | -24.91 | 6.02 | 4.53 | 5.16 | -2.71 | 0.7268 | 0.5286 | 7.55 | 0.8576 | 59.41 | 6.38 | 9.83 | 300.44 | 3.22 | 5.67 | 9.50 |
| Alnylam Pharmaceuticals, Inc. | 345.18m | -846.17m | 15.84bn | 1.32k | -- | 11.29 | -- | 45.90 | -7.57 | -7.57 | 3.08 | 12.10 | 0.1134 | 0.8579 | 6.91 | 260,907.00 | -27.79 | -35.69 | -31.47 | -39.36 | 85.34 | -- | -245.14 | -600.53 | 5.42 | -632.03 | 0.00 | -- | 193.36 | 34.16 | -16.24 | -- | 32.78 | -- |
| Incyte Corporation | 2.39bn | -191.07m | 20.33bn | 1.46k | -- | 8.65 | -- | 8.52 | -0.9112 | -0.9112 | 10.93 | 10.75 | 0.7752 | 8.87 | 6.61 | 1,639,780.00 | -6.20 | 3.65 | -7.30 | 4.37 | 95.75 | 96.02 | -8.00 | 4.76 | 3.70 | -- | 0.0216 | 0.00 | 14.71 | 33.37 | 308.16 | -- | 22.87 | -- |
| AmerisourceBergen Corp. | 186.29bn | 1.57bn | 21.14bn | 22.00k | 13.68 | 5.48 | 10.59 | 0.1135 | 7.57 | 7.57 | 893.43 | 18.91 | 4.70 | 15.71 | 13.86 | 8,467,589.00 | 3.98 | 2.11 | 16.08 | 8.73 | 2.62 | 2.78 | 0.8467 | 0.4435 | 0.5899 | 12.83 | 0.5106 | 43.62 | 6.94 | 8.48 | -21.75 | 23.77 | 3.24 | 11.22 |
| BioMarin Pharmaceutical Inc. | 1.85bn | 122.26m | 21.19bn | 3.00k | 177.55 | 6.54 | 91.16 | 11.47 | 0.658 | 0.658 | 10.07 | 17.87 | 0.381 | 0.6082 | 4.87 | 615,492.80 | 2.52 | -4.79 | 2.90 | -5.56 | 78.23 | 80.38 | 6.62 | -15.01 | 2.34 | -7.24 | 0.3096 | -- | 14.27 | 17.86 | 69.11 | -- | 6.90 | -- |
| McKesson Corporation | 231.00bn | 922.00m | 24.82bn | 80.00k | 27.93 | 4.55 | 12.12 | 0.1074 | 5.48 | 5.47 | 1,310.65 | 33.62 | 3.87 | 13.19 | 12.47 | 2,887,525.00 | 1.91 | 2.83 | 5.75 | 8.00 | 5.17 | 5.53 | 0.4926 | 0.7993 | 0.5719 | 1.69 | 0.5131 | 18.06 | 7.81 | 5.23 | 1,809.43 | -12.59 | -1.47 | 10.76 |
| Seattle Genetics, Inc. | 1.02bn | -255.68m | 26.71bn | 1.61k | -- | 14.71 | -- | 26.30 | -1.50 | -1.50 | 5.93 | 10.43 | 0.5442 | 1.23 | 4.30 | 632,759.50 | -13.70 | -14.09 | -15.84 | -16.76 | 90.11 | 90.52 | -25.18 | -27.33 | 4.39 | -- | 0.00 | -- | 40.02 | 26.17 | 28.76 | -- | 32.73 | -- |
| Moderna Inc | 105.84m | -487.25m | 27.21bn | 830.00 | -- | 9.20 | -- | 257.13 | -1.40 | -1.40 | 0.3027 | 7.49 | 0.0409 | -- | 5.59 | 127,519.30 | -18.84 | -- | -20.10 | -- | -- | -- | -460.36 | -- | -- | -- | 0.0226 | -- | -55.42 | -- | -27.91 | -- | -- | -- |
| Iqvia Holdings Inc | 10.94bn | 132.00m | 31.15bn | 67.00k | 244.52 | 5.57 | 22.25 | 2.85 | 0.6661 | 0.6661 | 55.91 | 29.23 | 0.473 | -- | 4.58 | 163,268.70 | 0.7049 | 1.50 | 0.8491 | 1.83 | 33.44 | 33.19 | 1.49 | 2.88 | -- | 1.72 | 0.6742 | 0.00 | 6.49 | 15.22 | -14.73 | -11.73 | 47.75 | -- |
Data as of Aug 13 2020. Currency figures normalised to Moderna Inc's reporting currency: US Dollar USD
23.64%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Mar 2020 | 24.76m | 6.37% |
| The Vanguard Group, Inc.as of 31 Mar 2020 | 20.39m | 5.25% |
| BlackRock Fund Advisorsas of 31 Mar 2020 | 11.55m | 2.97% |
| Th�l�me Partners LLPas of 31 Mar 2020 | 8.93m | 2.30% |
| SSgA Funds Management, Inc.as of 31 Mar 2020 | 5.50m | 1.41% |
| Federated Global Investment Management Corp.as of 31 Mar 2020 | 4.67m | 1.20% |
| Invesco Advisers, Inc.as of 31 Mar 2020 | 4.40m | 1.13% |
| Morgan Stanley Investment Management, Inc.as of 31 Mar 2020 | 4.21m | 1.08% |
| Bellevue Asset Management AGas of 31 Mar 2020 | 3.95m | 1.02% |
| Baillie Gifford & Co.as of 31 Mar 2020 | 3.56m | 0.92% |
More ▼
Data from 31 Mar 2020 - 31 Mar 2020Source: FactSet Research Systems Inc.
